Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03706365 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03706365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03706365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
November 26, 2018
Completion date
December 31, 2026
Enrollment
393 (actual)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer